Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Indazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.95 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.53 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.48 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.48 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.48 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.95 |
| ▸ | CDK2 | P24941 | 1/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.79 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK3 | P49761 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indazole SCHEMBL29544348 | 1.00 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL110751 | 1.00 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL29355507 | 0.97 | — | — | |
| Indazole SCHEMBL1221882 | 0.97 | HSP90AA1 (1.00) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL6295 | 0.97 | — | — | |
| Indazole SCHEMBL5221603 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL9407408 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL5420749 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL21058156 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL7371212 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709623-B1 | MEDICAMENTS AND METHODS FOR TREATING CANCER | BOLD THERAPEUTICS INC (CA) | 2020-08-19 | — | — | EP | claimed |
| CN-103601759-B | A kind of preparation method being used for the treatment of ruthenium (III) complex compound of tumour | WUHAN LIBAORUI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2015-08-19 | — | — | CN | claimed |
| CN-103601759-A | Preparation method of ruthenium (III) complex for treating tumour | WUHAN LIBAORUI MEDICINE SCIENCE & TECHNOLOGY CO LTD | 2014-02-26 | — | — | CN | claimed |
| EP-1353932-A1 | COMPOSITIONS CONTAINING A RUTHENIUM(III) COMPLEX AND A HETEROCYCLE | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2003-10-22 | — | — | EP | claimed |
| WO-2002059135-A1 | COMPOSITIONS CONTAINING A RUTHENIUM(III) COMPLEX AND A HETEROCYCLE | FAUSTUS FORSCHUNGS CIE. (DE) | 2002-08-01 | — | — | WO | claimed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | claimed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-111171047-B | Fused dihydro-4H-pyrazolo [5,1-C ] [1,4] oxazinyl compounds for the treatment of CNS disorders | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116265458-A | Benzothiophene derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| EP-4178963-A1 | 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Remix Therapeutics Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-116096723-A | Heterocyclic compounds useful as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2000002863-A1 | METHOD FOR PRODUCING CARBONYL DIIMIDAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
| EP-0792879-A1 | HYDRATE FOR MEDICINAL USE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| US-5356860-A | Styrene derivatives useful as herbicides and defoliants | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-18 | — | — | US | disclosed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | disclosed |
| EP-0302423-A2 | 1-Phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
| EP-0170412-A1 | Benzoselenino[4,3,2-cd]indazole compounds, compositions comprising the compounds and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-05 | — | — | EP | disclosed |
| EP-0014951-B1 | HETEROCYCLIC OXYPROPANOLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | HSP90AA1 403/4885FGFR1 1783/4885PARP1 3328/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | HSP90AA1 1122/4885FGFR1 723/4885PARP1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.